Dr. Govind Kaigala School of Biomedical Engineering, UBC



Dr. Govind Kaigala currently is an Associate Professor at the School of Biomedical Engineering, University of British Columbia, Vancouver. He is concurrently a PI at the Life Sciences Institute, a Senior Scientist at the Vancouver Prostate Center and an associated member of the BC Cancer Research Center. He is an earned his PhD from the departments of Electrical and Computer Engineering and Oncology (Cross Cancer Institute) in 2009 from the University of Alberta where he developed microfluidic systems for genetic analysis. He completed an NSERC Postdoctoral Fellowship at Stanford University between the Microfluidics Laboratory in the Dept. of Mechanical Engineering and Dept. of Urology at the Stanford Medical School (VA Hospital). In 2010 he joined the Research laboratory of IBM in Zurich where he was a Staff Scientist and a

Principal Investigator leading a team of researchers in the area of Precision Diagnostics. He participated regularly in student training and was a recognized PhD advisor at ETH-Z, EPFL and Technion University. Dr. Kaigala has authored and co-authored 80 papers in refereed journals and co-authored a book on open-space microfluidics. He has been the co-author on over 45 families of patents and his work has influenced the design of biotech products in the industry in the field of hematology and protein analysis. In recognition of his development of intellectual property, Dr. Kaigala was named "master inventor" by IBM in 2019. His research is in the areas of microscale fluid control, microscale molecular assays and technologies for personalized medicine and is passionate about translational clinical/medical research. With his team, he strives to bring quantitation in biology and medicine by leveraging bioinstrumentation and micro-and nanosystems. He received several recognitions, including > 10 awards while at IBM, Fellow of the Royal Society of Chemistry in 2020, and the Analytical Young Innovator Award from the American Chemical Society in 2023.

Last updated: 14 Dec. 2023